Morgan Stanley restated their equal weight rating on shares of Bruker (NASDAQ:BRKR) in a report issued on Thursday. They currently have a $35.00 price target on the medical research company’s stock.

A number of other research analysts have also weighed in on BRKR. BidaskClub upgraded shares of Bruker from a hold rating to a buy rating in a research note on Wednesday, August 16th. Goldman Sachs Group reiterated a sell rating and issued a $24.00 price objective on shares of Bruker in a research note on Tuesday, September 26th. J P Morgan Chase & Co upgraded shares of Bruker from an underweight rating to a neutral rating and set a $28.00 price objective for the company in a research note on Friday, November 3rd. Bank of America upgraded shares of Bruker from an underperform rating to a neutral rating and set a $34.00 price objective for the company in a research note on Friday, November 3rd. Finally, Cowen reiterated a hold rating and issued a $29.00 price objective on shares of Bruker in a research note on Friday, November 3rd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have assigned a buy rating to the stock. Bruker has a consensus rating of Hold and a consensus price target of $30.08.

Bruker (BRKR) traded up $0.73 during trading hours on Thursday, hitting $34.63. 713,448 shares of the company were exchanged, compared to its average volume of 548,629. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60. The company has a market cap of $5,387.15, a PE ratio of 29.60, a PEG ratio of 2.93 and a beta of 1.12. Bruker has a 52 week low of $21.03 and a 52 week high of $36.53.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.02. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The business had revenue of $435.60 million during the quarter, compared to analyst estimates of $415.45 million. During the same period in the previous year, the business earned $0.32 EPS. Bruker’s revenue was up 10.6% compared to the same quarter last year. sell-side analysts anticipate that Bruker will post 1.19 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 22nd. Stockholders of record on Monday, December 4th will be given a dividend of $0.04 per share. The ex-dividend date of this dividend is Friday, December 1st. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.46%. Bruker’s dividend payout ratio (DPR) is currently 17.02%.

Several institutional investors and hedge funds have recently added to or reduced their stakes in BRKR. AJO LP purchased a new position in shares of Bruker during the 2nd quarter valued at $46,075,000. First Trust Advisors LP grew its position in shares of Bruker by 1,689.7% during the 3rd quarter. First Trust Advisors LP now owns 502,159 shares of the medical research company’s stock valued at $14,939,000 after purchasing an additional 474,101 shares in the last quarter. Prudential Financial Inc. grew its position in shares of Bruker by 292.8% during the 3rd quarter. Prudential Financial Inc. now owns 567,002 shares of the medical research company’s stock valued at $16,868,000 after purchasing an additional 422,660 shares in the last quarter. Koch Industries Inc. grew its position in shares of Bruker by 2,573.5% during the 2nd quarter. Koch Industries Inc. now owns 334,774 shares of the medical research company’s stock valued at $324,000 after purchasing an additional 322,252 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new position in shares of Bruker during the 2nd quarter valued at $6,806,000. Hedge funds and other institutional investors own 65.63% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/17/bruker-brkr-earns-equal-weight-rating-from-morgan-stanley.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Stock Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related stocks with our FREE daily email newsletter.